ReviewFrontiers in oncology2026
The enigma of squamous cell carcinoma of the colon: a case report and review.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Primary squamous cell carcinoma (SCC) of the colon is an exceptionally rare malignancy (<1% of colorectal cancers). Its infrequency has limited the development of standardized diagnostic and therapeutic guidelines; most evidence derives from individual case reports. Early recognition is challenging because clinical presentation often mimics more common colorectal tumors. Case Presentation: We describe a 72-year-old woman diagnosed with left-sided (sigmoid) SCC presenting with locally advanced pT4 disease who achieved >12 years of disease-free survival following left hemicolectomy and adjuvant modified FOLFOX-6 chemotherapy. To contextualize this case, we conducted a comprehensive review of 62 published reports meeting strict inclusion criteria. Most patients presented with nonspecific abdominal symptoms. Contrast-enhanced CT(Computed Tomography) and PET/CT (Positron Emission Tomography) were routinely used to define local disease and exclude other squamous primaries. Immunohistochemistry consistently demonstrated positivity for squamous markers (p63, p40, CK5/6) with relative absence of adenocarcinoma-associated markers (CK20, CDX2). Surgery was the primary treatment modality, while systemic chemotherapy was increasingly utilized in stage II-IV disease. Conclusion: Adjuvant chemotherapy may benefit select high-risk stage II patients with primary colonic SCC with high-risk features such as pT4 tumor penetration. as exemplified in this case. Consistent data collection, collaboration, and molecular characterization are essential to establish evidence-based treatment strategies for this uncommon malignancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.